ArticleJournal of pharmacy & bioallied sciences2025
Exploring Lymphocyte Immunotherapy as a Treatment for Recurrent Miscarriage: A Case Study of Immune System Modulation and Positive Clinical Pregnancy Rate.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026Review
- Immunotherapy and IVF Outcomes in Unexplained Recurrent Pregnancy Loss: A Systematic Review with Implications for Personalized Reproductive Medicine.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case study reviews the use of Lymphocyte Immunotherapy (LIT) in a 28-year-old female patient who had a history of recurrent first-trimester miscarriages and failed intracytoplasmic sperm injection (ICSI) cycles. She had good ovarian reserve, normal semen analysis, and negative autoimmune tests but experienced four early miscarriages, which suggested an immune-mediated issue. LIT was chosen as a treatment option to address the possibility of immune system dysregulation contributing to pregnancy loss. LIT is the process of infusing the husband's lymphocytes to promote maternal tolerance of paternal antigens, reducing the possibility of immune foetal rejection. A received LIT was performed six weeks prior to a fresh ICSI cycle, with successful fertilization and transfer of embryos. There is evidence that positive outcomes occurred in serial ultrasounds and hormone levels at 6, 8, and 12 weeks with subsequent birth at term of a healthy baby. This case points to the possibility of using LIT as a therapeutic intervention in the treatment of unexplained recurrent miscarriage in patients who had previously failed previous assisted reproductive treatments. While the mechanism of action for LIT remains unknown, it would seem to somehow modulate the immune responses so that pregnancy results in better outcomes. This case may thus provide new evidence for LIT as a possible management strategy for those with immune causes of recurrent pregnancy loss (RPL) but warrants additional studies to optimize its use and effectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.